Dapagliflozin + spironolactone
Dapagliflozin + spironolactone has been studied in 2 papers since 2026: 1 trial in people, 1 review; 2 in the past year. The newest paper, Aug 12, 2026: “Diabetes, Adiposity, and Functional Phenotypes in HFpEF: A Systematic Review of Recent Treatment-Response Evidence”.
5 new papers in 30 daysSee all 10 papers on dapagliflozin + spironolactone
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“Group C achieved a significantly greater UAER reduction compared to Group A and Group B (P < 0.05)”
None of its findings points the other way.
- 1 lab in 1 country
- Human trial1
Studies in people
1 study gave dapagliflozin + spironolactone to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases urinary albumin excretion rate down: Decreases hyperkalemia | Randomized trial72 weeks | 168 peopleelderlyOlder adults; on irbesartan background therapy | The American journal of the medical sciences, May 20, 2026 |
What did studies of dapagliflozin + spironolactone find?
2Studies of dapagliflozin + spironolactone measured 2 outcomes: hyperkalemia and urinary albumin excretion rate.
Hyperkalemia
downin humans1
1 study
Hyperkalemia
downin humans1
Dapagliflozin + spironolactone decreases hyperkalemia in humans (on irbesartan background therapy; relative to spironolactone-associated hyperkalemia).
“while attenuating the risk of spironolactone-associated hyperkalemia”
Human trialon irbesartan background therapy; relative to spironolactone-associated hyperkalemia72 weeks
The American journal of the medical sciences
Urinary albumin excretion rate
downin humans1
1 study
Urinary albumin excretion rate
downin humans1
Dapagliflozin + spironolactone decreases urinary albumin excretion rate in humans (on irbesartan background therapy).
“Group C achieved a significantly greater UAER reduction compared to Group A and Group B (P < 0.05)”
Human trialon irbesartan background therapy72 weeks
The American journal of the medical sciences